Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660341 | 0.84 | ASIC1 (0.41) | ASIC1F10AKR1C3AKR1C2PTGER4 | |
| SCHEMBL658627 | 0.79 | KLKB1 (0.40) | — | |
| SCHEMBL4070158 | 0.77 | ALDH1A1 (0.47) | ASIC1MAPTF10AKR1C3 | |
| SCHEMBL2688186 | 0.75 | GRN (0.57) | MAPTF10AKR1C3PTGER4 | |
| SCHEMBL1056343 | 0.75 | HDAC3 (0.43) | AKR1C3AKR1C2PTGER4 | |
| SCHEMBL14549306 | 0.75 | ALDH1A1 (0.63) | MAPTF10AKR1C3AKR1C2PTGER4 | |
| SCHEMBL2686357 | 0.72 | AKR1C3 (0.42) | ASIC1MAPTAKR1C3AKR1C2PTGER4 | |
| SCHEMBL29329022 | 0.72 | MAPT (0.43) | MAPTAKR1C3AKR1C2 | |
| SCHEMBL1197409 | 0.71 | KDM4E (0.52) | MAPT | |
| SCHEMBL1197408 | 0.71 | PTGS2 (0.50) | MAPTAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | TRPV1, CNR1, CNR2 | EPHX1 3741/4885ASIC1 38/4885MAPT 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.